The Integrated Forecasting and Analysis Tool   Login Now

Akorn

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Akorn are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Akorn, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers

Annual Sales WW - Sales Growth per Year (%)   Rank Product Generic Name Pharmacological Class 2006 2007 2007 Akorn 1 Tetanus Diphtheria vaccine diphtheria & tetanus vaccine Diphtheria & tetanus vaccine - 8   n/a       Note: Shaded Cells

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Akorn 1 Hepatitis B vaccine Systemic Anti-infectives Vaccines Hepatitis B vaccine Pre-clinical   2 MMR vaccine Systemic Anti-infectives Vaccines MMR vaccine Pre-clinical   3 Human Diploid Rabies Vaccine Systemic Anti-infectives Vaccines Rabies vaccine Pre-clinical

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Akorn   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 368 368        PE Ratio (diluted) - Normalised (x) (8.5) (44.8)        Valuing the Enterprise        Enterprise Value 372 372        Free Cash Flow (Pre-Dividends) 0 (1)        FCF Yield (%) (0.1%) (0.4%)    Forecast Financials   Income Statement      Total Revenues 44 71      Cost of Goods Sold (30) (44)      S,G & A (16) (19)      R&D (5) (12)      Other Income/ Expense - Net 0 (2)      EBIT - Normalised (6) (5)      Net Interest & Financial Items (2) (1)      Pre-tax Profits - Normalised (9) (6)      Income Before Taxes (9) (6)      Tax 0 0      Tax Rate (%) 0.2% 0.1%      Preferred Dividends (4) (1)      Net Income - Reported (13) (7)      Net Income - Normalised (13) (7)     Per Share Data      EPS - Diluted (0.49) (0.09)      EPS - Basic (0.49) (0.09)      EPS - Normalised (diluted) (0.49) (0.09)      EPS - Normalised (basic) (0.49) (0.09)      Avg. Shares Outstanding - Diluted 26.1 74.0      Avg. Shares Outstanding - Basic 26.1 74.0      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

Akorn, Inc. Receives NDA Approvable Letter for Akten(R) Ophthalmic Gel 3.5%   (Akorn)   04-Jun-2008 Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial   (Akorn)   23-May-2008 Akorn-Strides, LLC Announces FDA Approval for Flumazenil Injection USP, 0.1 mg/mL - 5mL and 10 mL Multiple Dose Vials   (Akorn)   14-May-2008 Akorn-Strides, LLC Announces FDA Approvals for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials   (Akorn)   24-Apr-2008 Akorn, Inc. Announces FDA Approval of Diclofenac Sodium Ophthalmic Solution 0.1%   (Akorn)   18-Apr-2008 Akorn, Inc. Announces FDA Approval of Ofloxacin Ophthalmic Solution USP, 0.3%   (Akorn)   16-Apr-2008 Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL   (Akorn)   19-Mar-2008 Akorn-Strides, LLC Announces FDA Approval for Tobramycin Injection USP, 80 mg/2mL and 1.2 grams/30mL   (Akorn)   12-Mar-2008 Akorn, Inc. Announces FDA Approval of Calcitriol Injection, 1 mcg/mL and 2 mcg/mL   (Akorn)   30-Jan-2008 Akorn, Inc. Announces First ANDA Submission For Serum Institute of India, Ltd.   (Akorn)   05-Dec-2007 Akorn, Inc. Announces FDA Approval for Unit Dose Preservative Free Tetanus Diphtheria Vaccine   (Akorn)   26-Nov-2007 Akorn, Inc. Announces Release of IC-Green(TM)   (Akorn)   26-Sep-2007 Akorn Announces Submission of an ANDA Drug Product Developed Jointly with Sofgen Pharmaceuticals   (Akorn)   07-Sep-2007 Akorn, Inc. Launches Tetanus Diphtheria Vaccine   (Akorn)   05-Sep-2007 Akorn, Inc. Announces FDA Approval of Ketotifen Fumarate Ophthalmic Solution, 0.025%   (Akorn)   27-Jul-2007 Akorn-strides, LLC Announces Its First ANDA Approval for Keterolac Tromethamine Injection USP, 15 Mg/ml and 30 Mg/ml   (Akorn)   17-Jul-2007 Akorn, Inc. Announces the New Drug Application (NDA) Filing for Akten®   (Akorn)   29-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Akorn Afluria influenza vaccine   Ak-Con naphazoline   Ak-Dilate phenylephrine   Ak-Flour fluorescein sodium   Ak-Pentolate cyclopentolate hydrochloride   Ak-Poly-Bac bacitracin & polymyxin   Ak-T-Caine tetracaine   Akten -   Ak-Tob tobramycin   Akwa Tears paraffin liquid   Alfenta alfentanil hydrochloride   Amiodarone amiodarone   Anti-D human monoclonal antibody Rho(D) immune globulin (human)   Anti-emetic product -   Bal-In-Oil dimercaprol   Bimatoprost bimatoprost   Bladder cancer vaccine -   Brimonidine tartrate brimonidine tartrate   Ca-DTPA pentetate calcium trisodium   Calcitriol injection calcitriol   Ciprofloxacin opthalmic solution ciprofloxacin   Cromolyn sodium solution cromolyn sodium   Cyanide antidote kit sodium nitrite, sodium thiosulfate & amyl nitrite   Diclofenac sodium opthalmic solution diclofenac   Diltiazem diltiazem   Ephedrine sulfate injection ephedrine   Erythromycin ointment erythromycin   Flumazenil Injection flumazenil   Fluress fluorescein sodium & benoxinate hydrochloride   Fosphenytoin sodium injection fosphenytoin   Gentak gentamicin   Hepatitis B vaccine hepatitis B vaccine   Human Diploid Rabies Vaccine rabies vaccine   Hydase hyaluronidase (bovine)   IC-Green indocyanine green   Inapsine droperidol   Ketorolac tromethamine injection ketorolac tromethamine   Ketotifen fumarate opthalmic solution ketotifen fumarate   Labetalol hydrochloride injection labetalol   Latanoprost latanoprost   Lidocaine hydrochloride jelly lidocaine   Lorazepam lorazepam   Midazolam hydrochloride midazolam   MMR vaccine MMR vaccine   Myochrysine gold sodium thiomalate   Neomycin, Polymyxin B Sulfates & Bacitracin zinc ointment neomycin, polymyxin & bacitracin   Ocusert pilocarpine   Ofloxacin ophthalmic solution ofloxacin   Ondansetron Injection ondansetron   Orphenadrine citrate injection orphenadrine citrate   Paremyd hydroxyamphetamine hydrobromide & tropicamide   Piroxicam piroxicam   Proparacaine hydrochloride proparacaine   Rabies Monoclonal antibody rabies immune globulin (human)   Sodium chloride ophthalmic solution sodium chloride   Sublimaze fentanyl   Sufenta sufentanil citrate   Tetanus Diphtheria vaccine diphtheria & tetanus vaccine   Timolol maleate sterile ophthalmic solution timolol maleate   Tobramycin injection tobramycin   Travoprost travoprost   Trimethoprim sulfate & polymyxin b sulfate sterile ophthalmic solution trimethoprim & polymyxin   Tropicacyl tropicamide   Vancomycin vancomycin   Zinc-DTPA pentetate zinc trisodium

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:52:54 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd